批准,证据和"非标签"设备的使用:专利孔圆形关闭故事
Andrew M Goldsweig1, Yihong Deng2, Xiaoxi Yao2
1Department of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA (A.M.G.).
Circulation. Cardiovascular quality and outcomes
|January 8, 2024
概括
专利形形 (PFO) 关闭率仍然很低,许多程序用于未经批准的指示. 需要改善协调,以促进已批准的用途和研究其他潜在的PFO关闭好处.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗器械使用情况 医疗器械使用情况
背景情况:
- 专利卵孔 (PFO) 关闭已被批准用于减轻中风,但用于其他疾病,如偏头痛.
- 评估PFO关闭趋势相对于监管批准和关键试验出版物至关重要.
研究的目的:
- 评估专利关闭率的趋势和这些程序的说明.
- 检查PFO关闭时间,监管批准和重大临床试验的发布之间的关系.
主要方法:
- 一项回顾性队列研究分析了2006-2019年美国商业保险数据.
- 根据程序前的覆盖范围,PFO关闭指示被分类为等级 (中风,偏头痛,TIA,其他).
主要成果:
- PFO关闭率略有增加,但仍然很低;近一半的关闭是因为未经批准的指示.
- 脑卒中/全身血栓塞是主要的症状 (58.6%),而偏头痛占8.8%.
- 关闭模式与临床出版物和设备批准状态的相关性较弱.
结论:
- PFO关闭的利用率很低,与监管和出版里程碑的联系很弱.
- 很大一部分PFO关闭是因为未经批准的指示,这引发了安全问题.
- 建议监管机构和付款人之间进行协调,以指导适当的利用和促进研究.
相关概念视频
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...


